Global Life Science Ventures

About The Fund

Global Life Science Ventures (GLSV) is a prominent independent venture capital firm that was exclusively focused on the life sciences sector. They specialized in providing support to early-stage groups, notably those emerging from universities, scientific institutions, or industry. They have a clear investment thesis that also involves backing selected later stage companies, which could include buy-out situations. GLSV offered more than just capital investment; they also extended finance, advice, and facilitated access to a network of expertise. With the management of funds totaling over 200 million, they played a significant role in the development of their portfolio companies. GLSV operated with a global perspective, having established a presence with offices in Germany and Switzerland and generating a collaborative environment as one team. Since their inception, GLSV has been involved in significant transactions, which include leading the series A financing for GlycArt Biotechnology in 2003, which led to a substantial trade sale where Roche acquired GlycArt for approximately CHF 235 million in 2005. Their first fund began its operation in 1996, and the initial investments were made in 18 companies, while the second fund, GLSV II, which began in 2001, concentrated its investments primarily in Europe and the United States, also in 18 companies. After the termination of the investment period, the firm exited the remaining assets in 2015 and is currently in liquidation with no new investments being sought. Throughout their operation, GLSV actively provided updates and news regarding portfolio companies, such as Pieris Pharmaceuticals' collaboration milestones and clinical study advancements, reflecting their commitment to not only financial but also strategic involvement in their investments.